Biomarker for detecting coronary artery collateral circulation level of acute myocardial infarction and application of biomarker

By detecting the LMP7 level of the immune proteasome subunit in the blood and the Rentrop scoring system, the problem of predicting coronary artery collateral circulation in acute myocardial infarction is solved, and a new prediction method is provided, which significantly improves the prognosis of patients with acute myocardial infarction.

CN118980653APending Publication Date: 2024-11-19BEIJING ANZHEN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411192274.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-28
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art lacks effective biological indicators to predict the level of coronary collateral circulation in acute myocardial infarction, making it difficult to screen and find out whether there is good coronary collateral circulation, affecting the prognosis of patients with acute myocardial infarction.

Method used

The immunoproteasome subunit LMP7 was used as a biomarker, and the expression level in the blood was detected, combined with the Rentrop scoring system and statistical analysis, and the standard value of LMP7 was determined to predict the benign and bad conditions of coronary collateral circulation.

Benefits of technology

It was successfully clarified that LMP7 can be used as a biomarker for predicting coronary collateral circulation in acute myocardial infarction, providing new targets to improve the prognosis of patients with myocardial infarction, and has important clinical value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118980653A_ABST
    Figure CN118980653A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicine, in particular to a biomarker for detecting the coronary artery collateral circulation level of acute myocardial infarction and application of the biomarker. Through coronary artery angiography Rentrop grading evaluation and by utilizing various statistical analysis means, it is clear that the immune proteasome subunit LMP7 can be used as a biomarker for predicting whether acute myocardial infarction coronary artery collateral circulation is good or not, and the judgment standard value of the immune proteasome subunit LMP7 is further determined. As a new target spot for preventing and treating acute myocardial infarction, the biomarker has great clinical value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to the field of medical technology, and in particular to a biomarker for detecting the level of coronary collateral circulation in acute myocardial infarction and an application thereof. Background Art

[0002] Acute myocardial infarction is a common cardiac emergency with high morbidity, disability and mortality rates, which seriously threatens the health of residents and consumes medical and social resources. It is a major public health problem worldwide. Although new drugs have emerged in an endless stream in recent years and the number of percutaneous coronary interventions has steadily increased, the current status of the prevention and treatment of acute myocardial infarction is not optimistic. Therefore, in-depth understanding of the occurrence and development mechanism of acute myocardial infarction and finding new intervention targets are still the key to the study of acute myocardial infarction.

[0003] The main pathophysiological changes of acute myocardial infarction include: acute ischemia leads to a large number of myocardial cell death (including necrosis, apoptosis, etc.), a large number of platelets and inflammatory cells infiltrate the necrotic and damaged sites, activate local cardiac fibroblasts to become myofibroblasts to produce collagen and other extracellular matrices, and degrade the extracellular matrix accompanied by the production and increased activity of matrix metalloproteinases. At the same time, a large number of angiogenesis around the infarction participate in post-infarction cardiac remodeling. Among them, the area of ​​myocardial infarction is the most important factor in determining the severity of a series of subsequent pathophysiological changes and the prognosis of patients with acute myocardial infarction. Therefore, clarifying how to effectively increase blood perfusion in the ischemic area in the early stage of myocardial infarction will reduce the area of ​​myocardial infarction, reduce the degree of cardiac damage, and have a profound impact on the prognosis of patients with acute myocardial infarction.

[0004] Coronary collateral circulation is a self-blood supply protection mechanism during myocardial ischemia. When acute coronary artery occlusion occurs, coronary collaterals can increase significantly within hours after the onset of symptoms and can be identified by coronary angiography. Good coronary collateral circulation (CCC) can reduce the infarct size in patients with myocardial infarction, improve ventricular function and prevent the formation of ventricular aneurysms. Compared with poor coronary collateral circulation, patients with acute myocardial infarction with good coronary collateral circulation have lower in-hospital, 30-day mortality and long-term mortality risks. Although the newly formed collateral circulation may not provide sufficient blood flow to the infarct area, it can limit the continued damage, reduce the burden of ischemia, and ultimately reduce mortality.

[0005] However, the current research on predicting the level of coronary collateral circulation is all related to chronic occlusive lesions. There is no good biological indicator to predict the level of coronary collateral circulation in acute myocardial infarction. Therefore, screening and discovering new markers of whether the acute coronary collateral circulation is good has great clinical value. Summary of the invention

[0006] In order to solve the above technical problems, the present disclosure provides a biomarker for detecting the level of coronary collateral circulation in acute myocardial infarction and its application.

[0007] The present disclosure provides a biomarker for detecting the level of coronary collateral circulation in acute myocardial infarction, including the immunoproteasome subunit LMP7.

[0008] The present disclosure also provides the use of a reagent for detecting the expression level of the immunoproteasome subunit LMP7 in the blood in the preparation of a product for predicting the level of coronary collateral circulation in acute myocardial infarction.

[0009] Furthermore, the criteria for determining the level of coronary collateral circulation in acute myocardial infarction include:

[0010] When the immunoproteasome subunit LMP7 is ≥3.824 ng / mL, the level of coronary collateral circulation in acute myocardial infarction is good, such as the immunoproteasome subunit LMP7 is 3.824, 4, 4.1, 4.2, 4.3, 4.4 or 4.5, but is not limited to the listed values, and other unlisted values ​​within the range are also applicable.

[0011] When the immunoproteasome subunit LMP7 is less than 3.824 ng / mL, the level of coronary collateral circulation in acute myocardial infarction is poor, such as the immunoproteasome subunit LMP7 is 3, 3.1, 3.2, 3.3, 3.4, 3.6 or 3.8, but is not limited to the listed values, and other unlisted values ​​within the range are also applicable.

[0012] Furthermore, the reagent also includes a horseradish peroxidase-conjugated antibody, a first substrate, a second substrate and a stop solution;

[0013] The main component of the first substrate includes urea peroxide;

[0014] The main component of the second substrate includes TMB working solution;

[0015] The stop solution includes sulfuric acid.

[0016] Compared with the prior art, the technical solution provided by the embodiments of the present disclosure has the following advantages:

[0017] The present invention uses Rentrop grading assessment of coronary angiography and a variety of statistical analysis methods to clarify that the immunoproteasome subunit LMP7 can be used as a biomarker to predict whether the coronary collateral circulation of acute myocardial infarction is good, and further determines the standard value of the immunoproteasome subunit LMP7. As a new target for the prevention and treatment of acute myocardial infarction, this biomarker has great clinical value. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the present disclosure and, together with the description, serve to explain the principles of the present disclosure.

[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.

[0020] Figure 1 This is a diagram showing the difference in levels of the immunoproteasome subunit LMP7 in good acute myocardial infarction coronary artery collateral circulation and poor acute myocardial infarction coronary artery collateral circulation as described in the embodiments of the present disclosure.

[0021] Figure 2 This is a ROC curve diagram of the immunoproteasome subunit LMP7 described in the embodiments of the present disclosure for predicting good coronary collateral circulation in acute myocardial infarction.

[0022] Figure 3 This is a restricted cubic spline plot of the immunoproteasome subunit LMP7 and good coronary collateral circulation in acute myocardial infarction as described in the embodiments of the present disclosure. DETAILED DESCRIPTION

[0023] In order to more clearly understand the above-mentioned objectives, features and advantages of the present disclosure, the scheme of the present disclosure will be further described below. It should be noted that the embodiments of the present disclosure and the features in the embodiments can be combined with each other without conflict.

[0024] In the following description, many specific details are set forth to facilitate a full understanding of the present disclosure, but the present disclosure may also be implemented in other ways different from those described herein; it is obvious that the embodiments in the specification are only part of the embodiments of the present disclosure, rather than all of the embodiments.

[0025] The ubiquitin-proteasome system is an ATP-dependent protein degradation system widely present in eukaryotic cells, and is involved in regulating a variety of physiological processes such as cell cycle, gene transcription, antigen presentation, cell proliferation and differentiation, and signal transduction. Its catalytic core 20S proteasome is composed of two outer ring chains and two inner ring chains stacked together to form a barrel structure. The protease activities corresponding to subunits 1, 2, and 5 are cysteine ​​protease activity, trypsin activity, and chymotrypsin activity, respectively, which is the location of the catalytic center. Under the stimulation of inflammatory response, oxidative stress, etc., subunits 1, 2, and 5 are replaced by 1i (LMP2 or PSMB9), 2i (LMP10, PSMB10 or MECL1), and 5i (LMP7 or PSMB8) to become immunoproteasomes. Immunoproteasomes are synthesized rapidly when needed, and can quickly return to the basal state level when not needed to meet stress needs.

[0026] Endothelial cell activation is closely related to the generation of coronary collateral circulation, and the immunoproteasome subunit LMP7 (an antigen) has a certain relationship with endothelial cell function. Carfilzomib, an inhibitor of β5 and β5i subunits, may cause adverse events related to endothelial dysfunction, such as hypertension, heart failure, and coronary artery disease, in the treatment of multiple myeloma. In addition, in the hearts of diabetic mice, the use of LMP7 inhibitor ONX-0914 can restore endothelial cell characteristics and inhibit the transformation of endothelial cells to mesenchymal cells. Inflammatory cells also play an important role in the formation of coronary collateral circulation. Activated endothelial cells can attract inflammatory cells, mainly monocytes, and secrete various transcription factors, chemokines, and growth factors to stimulate the growth and development of endothelial cells and smooth muscle cells and ultimately mature collateral circulation. Many studies have reported the important role of LMP7 in inflammation. For example, in a diabetic nephropathy model, inhibition of LMP7 can downregulate the transcription of pro-inflammatory molecules in mesangial cells. In a mouse model of myocarditis, immunoproteasome deficiency reduced inflammatory, proinflammatory, and chemokine production. Functional T cells are important inflammatory cells in arteriogenesis, and ONX-0914, an inhibitor of LMP7, can limit CD4 + T cells differentiate into pro-inflammatory Th1 and Th17 helper T cells.

[0027] In summary, the immunoproteasome subunit LMP7 is expected to become a marker for diagnosing the quality of coronary collateral circulation in acute myocardial infarction.

[0028] Example

[0029] The present disclosure clarifies whether the immunoproteasome subunit LMP7 can be used to predict coronary collateral circulation in acute myocardial infarction through the following method.

[0030] 1. Sample collection

[0031] From April 2021 to April 2024, 4 ml of peripheral blood was collected from 252 patients with ST-segment elevation myocardial infarction (STEMI) at Beijing Anzhen Hospital, China.

[0032] The inclusion criteria for the STEMI group were as follows: diagnosis of STEMI and percutaneous coronary intervention (PCI) within 12 hours of chest pain onset. The diagnosis of STEMI was made by experienced emergency physicians based on symptoms, signs, electrocardiogram changes, and elevated cardiac biomarkers. The final diagnosis of STEMI was confirmed by coronary angiography (CAG). The exclusion criteria were as follows:

[0033] (1) Previous myocardial infarction, heart failure, previous PCI, coronary artery bypass grafting, or heart transplantation;

[0034] (2) history of cardiomyopathy and valvular heart disease;

[0035] (3) previous history of stroke, transient ischemic attack, intracerebral hemorrhage, subarachnoid hemorrhage, and other brain diseases;

[0036] (4) Patients with a history of inflammatory or infectious diseases, liver or kidney failure, cancer, or other diseases with an expected survival period of less than 1 year;

[0037] (5) Unwilling to participate.

[0038] The trial was approved by the Ethics Committee of Beijing Anzhen Hospital (GZR-2-093) and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.

[0039] 2. Assessment of coronary collateral circulation in patients with STEMI:

[0040] For all STEMI patients mentioned above, their angiographic results and coronary collateral circulation (CCC) were evaluated by two experienced interventional cardiologists who were blinded to the patients' clinical data. The extent of the coronary artery loops was evaluated using the Rentrop scoring system:

[0041] Rentrop 0, representing no filling of any artery;

[0042] Rentrop 1, representing the observation of collateral arterial filling but not reaching the epicardial segment;

[0043] Rentrop 2, representing the observation of partial filling of the epicardial artery;

[0044] Rentrop 3, representing complete filling of the epicardial arteries.

[0045] Rentrop 0 and Rentrop 1 were classified into the poor acute myocardial infarction coronary artery collateral circulation group (referred to as the poor CCC group), and Rentrop 2 and Rentrop 3 were classified into the good acute myocardial infarction coronary artery collateral circulation group (referred to as the good CCC group).

[0046] The evaluation results of the Rentrop scoring system are shown in Table 1:

[0047] Table 1

[0048]

[0049] 3. Detection of the level of immunoproteasome subunit LMP7

[0050] 252 samples were tested in batches using the following method;

[0051] S1: Set up 12 standard wells and 84 sample wells in a 96-well assay plate, add the standard (recombinant multifunctional peptidase 7 antigen of Escherichia coli, catalog number: ml060345) and samples (50 μl each) into the corresponding wells;

[0052] S2: 100 μl of horseradish peroxidase (HRP)-conjugated antibody was added to each standard well and each sample well except the blank well;

[0053] S3: After incubation at 37°C for 60 minutes, 350 μl of washing solution (PBS solution containing 0.15% Tween20, product number: ml060345) was added to each well and washed 5 times;

[0054] S4: After washing, add the first substrate (main component: carbamide peroxide, catalog number: ml060345) and the second substrate (main component: TMB working solution, catalog number: ml060345) (50 μl each) to the standard wells and sample wells, respectively, and then incubate at 37°C in the dark for 15 minutes;

[0055] S5: Then, add 50 μl of stop solution (2 mol / L dilute sulfuric acid, catalog number: ml060345) to the standard well and sample well respectively, immediately measure the OD value at a wavelength of 450 nm, and use the standard curve to calculate the concentration of the immunoproteasome subunit LMP7 in the sample. The results are as follows: Figure 1 shown.

[0056] Depend on Figure 1 It can be seen that the concentration of immunoproteasome subunit LMP7 was higher in the good acute myocardial infarction coronary artery collateral circulation group [3.83, (2.55, 4.61)] than in the poor acute myocardial infarction coronary artery collateral circulation group [2.59, (1.74, 3.41)].

[0057] 4. Statistical analysis

[0058] (1) Based on the LMP7 concentration of the above-mentioned poor acute myocardial infarction coronary artery collateral circulation group and good acute myocardial infarction coronary artery collateral circulation group, non-normal distribution continuous variables were expressed as medians and quartiles, and analyzed using the Mann-Whitney U test. Among them, IBM SPSS Statistics 29.0.1.0-Nonparametric Test-Old Dialog-2 Independent Samples was used, and whether the acute myocardial infarction coronary artery collateral circulation was good was used as the grouping variable, and the LMP7 concentration level was used as the test variable. The results showed that P < 0.05, indicating that the LMP7 concentration level in the good myocardial infarction coronary artery collateral circulation group was higher than that in the poor acute myocardial infarction coronary artery collateral circulation group.

[0059] (2) The receiver operating characteristic curve (ROC curve) was used to determine the optimal cutoff value of plasma immunoproteasome subunit LMP7 for predicting good coronary collateral circulation in acute myocardial infarction, and the corresponding sensitivity and specificity values ​​were obtained. Figure 2 As shown in the figure, the area under the curve (AUC) of the immunoproteasome subunit LMP7 [0.732 (0.67-0.794)] is relatively high and has a certain diagnostic value. At the same time, the optimal critical value of LMP7 was obtained by the Youden index (sensitivity + specificity - 1). The ROC curve corresponds to a maximum Youden index of 0.38, a specificity of 0.876, and a sensitivity of 0.504, and the optimal critical value of the immunoproteasome subunit LMP7 was determined to be 3.824 ng / mL.

[0060] (3) To examine the dose-response relationship between the immunoproteasome subunit LMP7 and good coronary collateral circulation in acute myocardial infarction, a restricted cubic spline curve (RCS curve) with four fixed nodes at the 5th, 35th, 65th, and 95th percentiles was used. The results are shown in Figure 2. Figure 3 As shown. Taking 3.824 ng / mL as the reference value, when the immunoproteasome subunit LMP7 ≥ 3.824 ng / mL, the J-shaped restricted cubic spline plot showed a monotonically increasing trend, and the OR value increased rapidly, while when LMP7 < 3.824 ng / mL, no obvious correlation was observed; this indicates that the immunoproteasome subunit LMP7 ≥ 3.824 ng / mL can be used to predict good coronary collateral circulation in acute myocardial infarction, and has important clinical value.

[0061] (4) A two-tailed P value less than 0.05 was considered statistically significant.

[0062] This disclosure used IBM SPSS Statistics version 29.0.1.0 and R version 4.3.1 for statistical analysis.

[0063] It should be noted that, in this article, relational terms such as "first" and "second" are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, the elements defined by the sentence "comprise a ..." do not exclude the existence of other identical elements in the process, method, article or device including the elements.

[0064] The above description is only a specific embodiment of the present disclosure, so that those skilled in the art can understand or implement the present disclosure. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present disclosure. Therefore, the present disclosure will not be limited to the embodiments described herein, but will conform to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A biomarker for detecting the level of coronary collateral circulation in acute myocardial infarction, characterized in that: Includes the immunoproteasome subunit LMP7.

2. The use of a reagent for detecting the expression level of the immunoproteasome subunit LMP7 in the blood in the preparation of a product for predicting the level of coronary collateral circulation in acute myocardial infarction.

3. The use according to claim 2, characterized in that: The criteria for determining the level of coronary collateral circulation in acute myocardial infarction include: When the immunoproteasome subunit LMP7 is ≥ 3.824 ng / mL, the level of coronary collateral circulation in acute myocardial infarction is good; When the immunoproteasome subunit LMP7 is less than 3.824 ng / mL, the level of coronary collateral circulation in acute myocardial infarction is poor.

4. The use according to claim 2 or 3, characterized in that: The reagents also include horseradish peroxidase-conjugated antibody, a first substrate, a second substrate and a stop solution; The main component of the first substrate includes urea peroxide; The main component of the second substrate includes TMB working solution; The stop solution includes sulfuric acid.